Abiopharma

🔍 Stein Jeffrey (Director)

Company: Cidara Therapeutics, Inc. (CDTX)

Report Date: 2016-05-23

Detailed Transactions and Holdings:

• Sold 270 shares of Common Stock (Direct)
  Date: 2016-05-23 | Code: J | equity_swap_involved: 0 | shares_owned_after: 10,025.00 | transaction_form_type: 4 | Footnotes: F1, F2, F1
• Sold 645 shares of Common Stock at $155.0 per share (Direct)
  Date: 2017-03-31 | Code: J | equity_swap_involved: 0 | shares_owned_after: 9,380.00 | transaction_form_type: 4 | Footnotes: F3, F2, F2
• Acquired 645 shares of Common Stock at $155.0 per share (Direct)
  Date: 2017-03-31 | Code: P | equity_swap_involved: 0 | shares_owned_after: 65,754.00 | transaction_form_type: 4 | Footnotes: F3, F2, F2
• Sold 750 shares of Common Stock at $118.948 per share (Direct)
  Date: 2017-06-05 | Code: J | equity_swap_involved: 0 | shares_owned_after: 8,630.00 | transaction_form_type: 4 | Footnotes: F4, F2, F2
• Acquired 750 shares of Common Stock at $118.948 per share (Direct)
  Date: 2017-06-05 | Code: P | equity_swap_involved: 0 | shares_owned_after: 66,504.00 | transaction_form_type: 4 | Footnotes: F4, F2, F2
• Sold 367 shares of Common Stock at $135.8 per share (Direct)
  Date: 2017-09-12 | Code: J | equity_swap_involved: 0 | shares_owned_after: 8,263.00 | transaction_form_type: 4 | Footnotes: F5, F2, F2
• Acquired 367 shares of Common Stock at $135.8 per share (Direct)
  Date: 2017-09-12 | Code: P | equity_swap_involved: 0 | shares_owned_after: 66,871.00 | transaction_form_type: 4 | Footnotes: F5, F2, F2
• Sold 2,500 shares of Common Stock at $40.006 per share (Direct)
  Date: 2020-11-10 | Code: J | equity_swap_involved: 0 | shares_owned_after: 5,763.00 | transaction_form_type: 4 | Footnotes: F6, F2, F2
• Acquired 2,500 shares of Common Stock at $40.006 per share (Direct)
  Date: 2020-11-10 | Code: P | equity_swap_involved: 0 | shares_owned_after: 69,371.00 | transaction_form_type: 4 | Footnotes: F6, F2, F2
• Sold 658 shares of Common Stock (Direct)
  Date: 2020-12-10 | Code: J | equity_swap_involved: 0 | shares_owned_after: 1,442.00 | transaction_form_type: 4 | Footnotes: F7, F2
• Sold 1,873 shares of Common Stock (Direct)
  Date: 2021-12-31 | Code: G | equity_swap_involved: 0 | shares_owned_after: 67,498.00 | transaction_form_type: 4 | Footnotes: F8, F2
• Acquired 937 shares of Common Stock (Direct)
  Date: 2021-12-31 | Code: G | equity_swap_involved: 0 | shares_owned_after: 2,379.00 | transaction_form_type: 4 | Footnotes: F8, F2

Footnotes:

• F1: Form 4 originally filed on May 23, 2016 erroneously overstated the Amount of Securities Beneficially Owned by Reporting Person.
• F2: The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024.
• F3: Form 4 originally filed on April 4, 2017 erroneously reported the securities as purchased by Reporting Person rather than by trust.
• F4: Form 4 originally filed on June 7, 2017 erroneously reported the securities as purchased by Reporting Person rather than by trust.
• F5: Form 4 originally filed on September 12, 2017 erroneously reported the securities as purchased by Reporting Person rather than by trust.
• F6: Form 4 originally filed on November 10, 2020 erroneously reported the securities as purchased by Reporting Person rather than by trust.
• F7: Form 4 originally filed on March 19, 2021 erroneously reported a 26,300 share gift as a holding rather than a transaction and further overstated the holdings received by son by 13,150 shares.
• F8: This transaction involved a gift of securities by the Reporting Person to his sons, one of which is economically dependent on the Reporting Person. The Reporting Person disclaims beneficial ownership of the shares held by his independent son, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his independent son's shares for purposes of Section 16 or for any other purpose.